TYRA

AI MemoPost-earnings T+3

Tyra Biosciences

As of 2026-08-08/Post-earnings T+3/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-08 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

SURF302 initial Phase 2 readout expected in September 2026 • 2026-09-30

Base target: $24 / p=50% prob

Biggest risk

The investment case remains highly dependent on binary clinical outcomes. BEACH301 timing has slipped, SURF303 data are distant, and no confirmed post-print analyst revisions or consensus surprise are available.

Invalidation

Break below $14 or thesis failure.

What would change my mind?

September SURF302 data could validate oral dabogratinib in FGFR3-altered IR NMIBC, while the broader three-program strategy and cash runway into the second half of 2028 support continued execution [#SEC-8K-2026-08-04].

Research note

Recommendation

—

Confidence

medium

As of

2026-08-08

Base target

$24

p=50%

Bull target

$43

p=25%

Bear target

$14

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

BEACH301 readout delayed to end-Q1 2027
SURF303 remains a 2027 development milestone
September SURF302 data could validate oral dabogratinib in FGFR3-altered IR NMIBC, while the broader three-program strategy and cash runway into the second half of 2028 support continued execution [#SEC-8K-2026-08-04].

BearKey bullets

BEACH301 timing has been pushed to end-Q1 2027 after progression to a fifth dose level.
No reliable consensus surprise, estimate revision, target revision, or trusted source-attributed post-print price reaction is available in the packet.
SURF302 efficacy or safety data could disappoint or prove difficult to interpret, producing a sharp downside reaction.

WatchKey bullets

SURF302 initial Phase 2 readout expected in September 2026

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $24 (p=50%)

Target spread vs base: +79% / -42%

Scenario probabilities

Bull Target: $43 (p=25%)Base Target: $24 (p=50%)Bear Target: $14 (p=25%)

Commentary

The post-earnings update is mixed: the September SURF302 readout remains intact and cash runway is strong, but BEACH301 data moved to end-Q1 2027 [#SEC-8K-2026-08-04]. Social coverage is unavailable, and analyst revision or consensus-surprise data are unavailable; missing reaction data is not positive evidence. This remains a cautious monitoring view ahead of SURF302.

As of 2026-08-08 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

BEACH301 readout delayed to end-Q1 2027
SURF303 remains a 2027 development milestone

Scenarios

Bull Target (Scenario probability)

$43 / p=25% prob

Base Target (Scenario probability)

$24 / p=50% prob

Bear Target (Scenario probability)

$14 / p=25% prob

Analysis 2026-08-08 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

-0.20

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-09-30
SURF302 initial Phase 2 readout expected in September 2026
Tyra expects initial safety results from more than 40 patients and efficacy results from more than 20 patients in the SURF302 study, making this the clearest near-term binary valuation test [#SEC-8K-2026-08-04].
Prob 85.00% • Move 25.00% • Priced-in 55.00%

Short-term Catalysts

Next few weeks

BEACH301 readout delayed to end-Q1 2027
2027-03-31
The safety-sentinel readout moved from Q4 2026 to end-Q1 2027 after opening a fifth dose level, reducing near-term catalyst density and potentially weighing on sentiment [#SEC-8K-2026-08-04].
Prob 100% • Move -8% • Priced-in 80%

Long-term Catalysts

Months to a year

SURF303 remains a 2027 development milestone
2027-12-31
The Phase 2a/b LG-UTUC program has begun dosing and could support a future NDA pathway, but efficacy remains unproven and initial results are not expected until 2027 [#SEC-8K-2026-08-04].
Prob 70% • Move 18% • Priced-in 25%

Risks

BEACH301 timing has been pushed to end-Q1 2027 after progression to a fifth dose level.
No reliable consensus surprise, estimate revision, target revision, or trusted source-attributed post-print price reaction is available in the packet.
SURF302 efficacy or safety data could disappoint or prove difficult to interpret, producing a sharp downside reaction.
The company remains clinical-stage, with regulatory, enrollment, execution, and pipeline-prioritization risk across multiple programs.

Peers

Symbol	Summary
MAZE	Clinical-stage biotech with similar market capitalization; useful for milestone and financing sensitivity, but not a direct FGFR3 or indication peer.
FBRX	Similarly sized biotechnology company; comparison is mainly for binary clinical risk and valuation behavior, not operating or therapeutic overlap.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-08

Loading AI feed…

Symbol

Summary

MAZE

Clinical-stage biotech with similar market capitalization; useful for milestone and financing sensitivity, but not a direct FGFR3 or indication peer.

FBRX

Similarly sized biotechnology company; comparison is mainly for binary clinical risk and valuation behavior, not operating or therapeutic overlap.